1. Home
  2. ITOS

ITOS

iTeos Therapeutics Inc.

Logo iTeos Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Founded: 2011 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 438.7M IPO Year: 2020
Target Price: $33.25 AVG Volume (30 days): 280.8K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.15 EPS Growth: N/A
52 Week Low/High: $8.20 - $18.24 Next Earning Date: 05-08-2024
Revenue: $12,595,000 Revenue Growth: -95.29%
Revenue Growth (this year): 102.46% Revenue Growth (next year): -97.47%

Share on Social Networks: